Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

trialsTrialRecruiting

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

A phase 1/2 trial of FMC-376 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Frontier Medicines Corporation, now recruiting.

Overview Connected7

Overview

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT06244771 by Frontier Medicines Corporation, with 403 participants planned, started 2024-02-12 and due to reach its primary completion in 2027-10. Interventions recorded: FMC-376.

Setting

An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors

Phase

Phase 1/2

Sponsor

Frontier Medicines Corporation

Registry

Started

2024-02-12

Enrolled

403 enrolled

Connected

Similar pages

Trial
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Pancreatic ductal adenocarcinoma and the tag pipeline.
Trial
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Shares KRAS G12C-mutant colorectal cancer, KRAS G12C-mutant non-small-cell lung cancer, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
An Open-label, Multicenter, Phase II Clinical Study to Evaluate HRS-7058 in Patients With Pancreatic Cancer
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Trial
Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases
Shares KRAS G12C-mutant colorectal cancer, Colorectal cancer and the tag pipeline.
Trial
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Trial
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
Shares Pancreatic ductal adenocarcinoma, Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.

cancers

Colorectal cancer KRAS G12C-mutant colorectal cancer KRAS G12C-mutant non-small-cell lung cancer KRAS G12C-mutant pancreatic ductal adenocarcinoma Non-small-cell lung cancer Pancreatic ductal adenocarcinoma

companies

Frontier Medicines

Evidence strength21/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
403 enrolled+13
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Registry trials now reach the 50 subtype pages added this… · diff · file

Sources & links

ClinicalTrials.gov NCT06244771

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Non-small-cell lung cancer
Colorectal cancer
Pancreatic ductal adenocarcinoma
KRAS G12C-mutant colorectal cancer
KRAS G12C-mutant non-small-cell lung cancer
KRAS G12C-mutant pancreatic ductal adenocarcinoma

Companies

Frontier Medicines

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct06244771/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct06244771.

WebMCP tools registered on this page: onco_search, onco_get_entity.